Kane Biotech Summarizes Compelling Oral Care Study Results

March 26, 2015

WINNIPEG, Manitoba (March 26, 2015) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms is pleased to provide a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations.


The dog efficacy study was a controlled, randomized, masked study with 30 dogs each per control and treatment groups. Both groups were fed normal diets, but the treatment group received drinking water containing Kane’s oral care water additive at the recommended dosage, while control group received normal water for consumption throughout the study period. On Day 0, dental prophylaxis was performed for each dog and calculus score was confirmed as a score of (0).Then calculus was measured on day 28, 56, 84 of the study period using modified Warrick-Gorrel method.


The mean calculus scores for the Company’s oral care water additive were better than the control throughout the study. On day 28, 56, and 84 the calculus score for the water additive was 14.2%, 23.5%, and 25.4% lower than the control group, respectively. The difference in calculus scores between the control and treatment group was statistically significant. In addition, no significant differences were observed between the two treatment groups for either animal body weights or food consumption.


• 25.4% reduction in calculus (p<0.0229)
• No change in body weight or food consumption
• The water additive is an effective first step in pet oral care


“We are very pleased to report our oral care water additive significantly reduces calculus with daily use” stated Gord Froehlich, President and CEO of Kane Biotech. “This is especially significant as a water additive is the first step in a good oral care program and combined with our new products in development Kane Biotech will offer a superior oral care program for your pets.”


The dog safety study was a randomized, masked laboratory study with three parallel treatment groups each contained 6 dogs. The product was administered as added to their drinking water at 0, 1 and 5 times the recommended application volume. Dogs were treated for a total of 30 consecutive days. Variables measured included clinical observations, physical examinations, oral assessments, body weights, and clinical pathology that include a comprehensive list of hematology and serum chemistry indices, and coagulation profile measured at regular time points during study period. With the exception of soft feces (noted intermittently for 3 of 6 dogs in the 5 times use rate group) findings documented during clinical observations, physical examinations and oral assessments were within normal limits. Trends were similar across treatment and control groups. Evaluation of clinical pathology indices revealed no group trends or individual effects which were considered treatment-related. In conclusion, the safety study successfully demonstrated the product is safe up to 5 times the recommended usage rate during the study period.


• Passed comprehensive safety assessment up to 5 times usage rate
• Contains ingredients that meet Health Canada’s LRVHP (Low Risk Veterinary Health Program)


“Better science leads to a healthier mouth and a happier pet and our new standard of oral care technology for pets is the best in the world” stated Gord Froehlich, President and CEO of Kane Biotech. “We are unique in having the only oral care water additive on the market with compelling science and proven efficacy combined with an unprecedented safety profile.”

About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development and commercialization of products that prevent and remove biofilms. Biofilms develop when bacteria and other microorganisms form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.


Kane Biotech uses patent protected technologies based on molecular mechanisms of biofilm formation/dispersal and methods for finding compounds that inhibit or disrupt biofilms. The Company has evidence that these technologies have potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
For more information, please contact:

Gord Froehlich
President & CEO
Kane Biotech Inc.
204-477-7592 phone
204-474-7552 fax
ir@kanebiotech.com
ww.kanebiotech.com
 

Share This Story

Back